Welcome to the Spring 2025 Notable New Drugs™ Report
This is the latest in our ongoing series of commentaries that highlight key new drugs. The drugs in this issue are expected to receive U.S. Food and Drug Administration (FDA) approval before the end of June 2025.
In this latest edition, we highlight key new drugs that are expected to receive U.S. Food and Drug Administration (FDA) approval before the end of June 2025. This includes:
- Nipocalimab is intended to treat generalized myasthenia gravis.
- Sebetralstat will provide for the on-demand treatment of hereditary angioedema attacks in adult and pediatric patients aged 12 years and older.
- Garadacimab is under review to prevent episodes of hereditary angioedema.
As always, our Optum Rx pipeline surveillance team continuously monitors and evaluates the drug development pipeline to share important upcoming drug approvals.
Please refer here for additional technical background and supplemental sources.
Don't want to read the full report?
Related healthcare insights
Report
Our report emphasizes new, next-gen and first-in-class treatments for cystic fibrosis, non-opioid treatment and GLP-1 drugs.
Article
New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.
![New Options to Treat Schizophrenia, COPD [Report]](/content/dam/o4-dam/images/professionals/pharmacies/clinician-on-ipad-with-microscope-1080x720.jpg)
Report
A clever combination drug offers new help for schizophrenia with reduced side effects, while Dupixent expands its footprint to COPD.